In clinical trials, NCT04336241, a genetically modified HSV-1 expressing anti-cytotoxic T-lymphocyte associated protein 4 (anti-CTLA-4) antibody, is being evaluated to directly destroy tumors and generate an anti-tumor immune response. This evidence concerns the gene CTLA4 and neoplasm.